<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305850</url>
  </required_header>
  <id_info>
    <org_study_id>162/53</org_study_id>
    <nct_id>NCT01305850</nct_id>
  </id_info>
  <brief_title>The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients</brief_title>
  <official_title>The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, placebo controlled, multi-center clinical trial to
      determine whether aliskiren or aliskiren plus losartan or enalapril plus losartan effects on
      peritoneal membrane transportation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description:

      Many peritoneal dialysis patients suffer from uremia due to inadequate dialysis or volume
      overload caused by failure of peritoneal membrane transportation. One of the most important
      etiologies of peritoneal membrane failure is unavoidable to use high glucose-containing
      dialysate solution that induces injury to mesothelial cells. Previous data found that injured
      mesothelial cell produced Angiotensin II inducing peritoneal inflammation and fibrosis.
      Blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibition or
      angiotensin receptor antagonism play a major role to slow these effects.

      Many trials in animal studies have proved the benefit of angiotensin-converting enzyme
      inhibition and angiotensin receptor antagonism in preservation of peritoneal membrane but
      clinical evidences in human are controversy in the past. Recently our data have demonstrated
      the roles of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism for
      slowing peritoneal membrane dysfunction in views of anatomy and solute transportation
      (abstract presentation in American Society of Nephrology 2010). These available data
      confirmed that renin-angiotensin system blockages were benefit. Nowadays, there is a new
      class of antihypertensive drug, called direct renin inhibitor . It blocks (pro)renin active
      site that is the rate- limiting step of renin-angiotensin system. We're interesting in this
      drug and wonder it can slow the peritoneal membrane dysfunction in continuous ambulatory
      peritoneal dialysis patients. Therefore, we design a study to show the effect of aliskiren
      alone or combination with angiotensin receptor antagonism for slowing peritoneal membrane
      dysfunction in naive continuous ambulatory peritoneal dialysis patients in several hospitals.
      Our study will be taken in 1 year duration and uses modified peritoneal equilibrium test and
      dialysate cancer antigen 125 (CA125) as indexes of peritoneal membrane transportations.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changing in modified peritoneal equilibrium test</measure>
    <time_frame>at the beginning, 6 months and 12 months</time_frame>
    <description>Modified peritoneal equilibrium test is the standard test for evaluation peritoneal membrane transportation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>appearance rate of dialysate CA125</measure>
    <time_frame>the begining, 6 months and 12 months</time_frame>
    <description>Appearance rate of dialysate CA125 refers to anatomical change of peritoneal. It can be calculated by multiplying dialysate CA125 with dialysate volume and deviding by dwell time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutritional status</measure>
    <time_frame>at the beginning, 6 months and 12 months</time_frame>
    <description>assess by serum albumin and subjective global assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>adverse events of the drugs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peritoneal Membrane Failure</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren plus Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril plus Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Aliskiren group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren plus Losartan</intervention_name>
    <description>Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg</description>
    <arm_group_label>Aliskiren plus Losartan</arm_group_label>
    <other_name>Aliskiren plus Losartan group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril plus Losartan</intervention_name>
    <description>Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg</description>
    <arm_group_label>Enalapril plus Losartan</arm_group_label>
    <other_name>Enalapril plus Losartan group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients received continuous ambulatory peritoneal dialysis less than one and a
             half years

          2. Subjects of either sex, more than 20 years old

          3. Hypertension

          4. Provision of written informed consent by subject or guardian

        Exclusion Criteria:

          1. No history of taking an angiotensin converting enzyme inhibitor or
             angiotensin-receptor blockers or aldosterone antagonist for at least 2 month

          2. Serum potassium more than 5.5 mEq/L

          3. History of renal artery stenosis

          4. Peritonitis or volume overload within the preceding 1 month

          5. Myocardial infarction within the preceding 6 months or clinically significant valvular
             disease or any active cardiovascular disease

          6. History of malignant hypertension or hypertensive encephalopathy or cerebrovascular
             accident within the preceding 6 months

          7. Any condition that may have precluded a patient from remaining in the study, such as
             alcohol or drug abuse, chronic liver disease, malignant disease, or psychiatric
             disorder

          8. History of allergy or intolerance to an angiotensin converting enzyme inhibitors or
             angiotensin receptor blockers

          9. Hypotension defined as systolic blood pressure less than 90 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Talerngsak Kanjanabuch, Assist. Prf.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pichaya Tantiyavarong, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Talerngsak Kanjanabuch, Assist. Prf.</last_name>
    <phone>662-2564321</phone>
    <phone_ext>211</phone_ext>
    <email>golfnephro@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talerngsak Kanjanabuch, Assist. Prf.</last_name>
      <phone>662-2564321</phone>
      <phone_ext>211</phone_ext>
      <email>golfnephro@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Talerngsak Kanjanabuch, Assist. Prf.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pichaya Tantiyavarong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Assist. Prf. Talerngsak Kanjanabuch, M.D / Department of nephrology, Division of Internal medicine, Faculty of medicine, Chulalongkorn University</name_title>
    <organization>Chulalongkorn University</organization>
  </responsible_party>
  <keyword>Aliskiren</keyword>
  <keyword>Losartan</keyword>
  <keyword>Peritoneal membrane dysfunction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

